Online inquiry

IVTScrip™ mRNA-Anti-FOLR1, IMGN853(Cap 0, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ9199MR)

This product GTTS-WQ9199MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets FOLR1 gene. The antibody can be applied in Ovarian Cancer research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Chimeric
RefSeq NM_000802.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2348
UniProt ID P15328
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-FOLR1, IMGN853(Cap 0, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ9199MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ14020MR IVTScrip™ mRNA-Anti-IL33, REGN-3500(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA REGN-3500
GTTS-WQ4932MR IVTScrip™ mRNA-Anti-GP, c13C6-FR1-N(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA c13C6-FR1-N
GTTS-WQ9392MR IVTScrip™ mRNA-Anti-IL2R, Interleukin 2(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA Interleukin 2
GTTS-WQ3614MR IVTScrip™ mRNA-Anti-FGFR2, BAY 1179470(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BAY 1179470
GTTS-WQ7834MR IVTScrip™ mRNA-Anti-GLP1R, GSK 716155(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA GSK 716155
GTTS-WQ1132MR IVTScrip™ mRNA-Anti-CD40, ABBV-927(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA ABBV-927
GTTS-WQ1054MR IVTScrip™ mRNA-Anti-TNFRSF10B, ABBV-621(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ABBV-621
GTTS-WQ15087MR IVTScrip™ mRNA-Anti-TNC, ST2146(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ST2146
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW